MediciNova (United States)

Recent papers from MediciNova (United States)

1. A44-15 Accelerating Evaluation of Exacerbation Risk Reduction in Asthma and COPD Trials With Real-time Clinical Assessments of the CompEx EndpointsAmerican Journal of Respiratory and Critical Care Medicine · 2026
2. Power Efficiency – Comparison between Pulse Forming Network and Solid-State Technology2026
3. Effect of MN-166 (ibudilast) on acute respiratory failure prevention in hospitalized participants with COVID-19: a randomized, double-blind, placebo-controlled phase 2 studyBMC Pulmonary Medicine · 2026
4. Enhancement of ABCA1 and ABCG1 Expression and Cholesterol Efflux by a Metabolite of Tipelukast: A Potential Therapeutic Strategy for AtherosclerosisJournal of Atherosclerosis and Thrombosis · 2025
5. Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM).Journal of Clinical Oncology · 2024
6. A major 6 Mb superlocus is involved in pyrethroid resistance in the common bed bug Cimex lectularius2023
7. MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis in a Phase IIb/III Study: COMBAT-ALS Study DesignNeurodegenerative Disease Management · 2021
8. Electroconvulsive therapy is associated with lower readmission rates in patients with schizophreniaBrain stimulation · 2021
9. Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trialNeuroImage Clinical · 2021
10. Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune SuppressionFrontiers in Immunology · 2020
11. Glioblastoma myeloid-derived suppressor cell subsets express differential macrophage migration inhibitory factor receptor profiles that can be targeted to reduce immune suppression2019
12. Effect of Ibudilast on Neurofilament-light Chain in Progressive MS: Analysis from a Phase II Trial (P3.2-033)Neurology · 2019
13. Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF)Scientific Reports · 2019
14. Phase 2 Trial of Ibudilast in Progressive Multiple SclerosisNew England Journal of Medicine · 2018
15. Feasibility of Energy Medicine in a Community Teaching Hospital: An Exploratory Case SeriesThe Journal of Alternative and Complementary Medicine · 2015
16. Non-clinical development of ozanezumab: a humanised antibody targeting the amino terminus of neurite outgrowth inhibitor A (Nogo-A)Toxicology Research · 2015
17. Codeine-induced hyperalgesia and allodynia: investigating the role of glial activationTranslational Psychiatry · 2014
18. Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependenceAddiction Biology · 2013
19. Reversal of Established Traumatic Brain Injury-Induced, Anxiety-Like Behavior in Rats after Delayed, Post-Injury Neuroimmune SuppressionJournal of Neurotrauma · 2013
20. Acute Neuroimmune Modulation Attenuates the Development of Anxiety-Like Freezing Behavior in an Animal Model of Traumatic Brain InjuryJournal of Neurotrauma · 2012